By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The US biosimilars market is gaining strong traction as healthcare systems seek cost-effective alternatives to branded biologic therapies. Biosimilars are biologic medical products that are highly similar to already approved reference biologics, with no clinically meaningful differences in terms of safety, purity, and efficacy.
As patents for blockbuster biologics continue to expire, biosimilars offer significant opportunities to expand access to life-saving treatments while reducing healthcare expenditure. The US biosimilars market is projected to grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2030.
The US biosimilars market can be segmented by product type, disease indication, manufacturing type, and end-user:
By Product Type:
By Disease Indication:
By Manufacturing Type:
By End-User:
The US biosimilars market is projected to grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2030. As cost containment becomes a priority in global healthcare, biosimilars are set to become a cornerstone of modern treatment protocols, driving access and affordability.
Other Regional Reports of Biosimilars Market: